Hesperidin-3′- O -methylether is more potent than hesperidin in phosphodiesterase inhibition and suppression of ovalbumin-induced airway hyperresponsiveness

Evidence-based Complementary and Alternative Medicine

Volumn 2012, Issue , 2012, Pages

  Yang, You Lan ^a   Hsu, Hsin Te ^b   Wang, Kuo Hsien ^b   Wang, Chao Sian ^a   Chen, Chien Ming ^a   Ko, Wun Chang ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AGLYCONE; BETA GLUCOSIDASE; FLAVANONE GLYCOSIDE; HESPERIDIN; HESPERIDIN 3 O METHYLETHER; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G2A; KETAMINE; OVALBUMIN; PHOSPHODIESTERASE; UNCLASSIFIED DRUG; XYLAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CONTROLLED STUDY; DRUG POTENCY; EOSINOPHIL; INFLAMMATORY CELL; LYMPHOCYTE; MACROPHAGE; MALE; NAUSEA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; VOMITING;

EID: 84874866580     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2012/908562     Document Type: Article

References (49)

1. Lee M. E., Markowitz J., Lee J. O., Lee H., Crystal structure of phosphodiesterase 4D and inhibitor complex. FEBS Letters 2002 530 1-3 53 58 2-s2.0-0037163858 10.1016/S0014-5793(02)03396-3 (Pubitemid 35248185)
2. Torphy T. J., Cieslinski L. B., Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. Molecular Pharmacology 1990 37 2 206 214 2-s2.0-0025092063 (Pubitemid 20082984)
3. Kapui Z., Schaeffer P., Mikus E. G., Boronkay E., Gyürky J., Herbert J. M., Pascal M., Experimental studies on guanosine 3',5'-cyclic monophosphate levels and airway responsiveness of the novel phosphodiesterase type 5 inhibitor SR 265579 in guinea-pigs. Arzneimittel-Forschung/Drug Research 1999 49 8 685 693 2-s2.0-0032804309 (Pubitemid 29400043)
4. de Boer J., Philpott A. J., Van Amsterdam R. G. M., Shahid M., Zaagsma J., Nicholson C. D., Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. British Journal of Pharmacology 1992 106 4 1028 1034 2-s2.0-0026741623
5. Silver P. J., Hamel L. T., Perrone M. H., Bentley R. G., Bushover C. R., Evans D. B., Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. European Journal of Pharmacology 1988 150 1-2 85 94 2-s2.0-0023880662
6. Kim E., Chun H. O., Jung S. H., Kim J. H., Lee J. M., Suh B. C., Xiang M. X., Rhee C. K., Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-asthmatics. Bioorganic and Medicinal Chemistry Letters 2003 13 14 2355 2358 2-s2.0-0038341865 10.1016/S0960-894X(03)00405-0 (Pubitemid 36724981)
7. Giembycz M. A., Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs 2000 59 2 193 212 2-s2.0-0034024182 (Pubitemid 30168507)
8. Robichaud A., Savoie C., Stamatiou P. B., Lachance N., Jolicoeur P., Rasori R., Chan C. C., Assessing the emetic potential of PDE4 inhibitors in rats. British Journal of Pharmacology 2002 135 1 113 118 2-s2.0-0036152721 (Pubitemid 34102104)
9. Robichaud A., Stamatiou P. B., Jin S. L. C., Lachance N., MacDonald D., Laliberté F., Liu S., Huang Z., Conti M., Chan C. C., Deletion of phosphodiesterase 4D in mice shortens α 2- adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. Journal of Clinical Investigation 2002 110 7 1045 1052 2-s2.0-0036790480 10.1172/JCI200215506
10. Ko W. C., Shih C. M., Lai Y. H., Chen J. H., Huang H. L., Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships. Biochemical Pharmacology 2004 68 10 2087 2094 2-s2.0-5144221343 10.1016/j.bcp.2004.06.030 (Pubitemid 39346198)
11. Knekt P., Kumpulainen J., Järvinen R., Rissanen H., Heliövaara M., Reunanen A., Hakulinen T., Aromaa A., Flavonoid intake and risk of chronic diseases. American Journal of Clinical Nutrition 2002 76 3 560 568 2-s2.0-0036721149 (Pubitemid 34920833)
12. Yen K. Y., Pharmacology of Common Chinese Medicine (III) 1971 Taipei, Taiwan National Research Institute of Chinese Medicine
13. Wei D., Ci X., Chu X., Wei M., Hua S., Deng X., Hesperidin suppresses ovalbumin-induced airway inflammation in a mouse allergic asthma model. Inflammation 2011 1 8 2-s2.0-79251542073 10.1007/s10753-011-9295-7
14. Ko W. C., Chen M. C., Wang S. H., Lai Y. H., Chen J. H., Lin C. N., 3- O -methylquercetin more selectively inhibits phosphodiesterase subtype 3. Planta Medica 2003 69 4 310 315 2-s2.0-0037616054 10.1055/s-2003-38874 (Pubitemid 36577995)
15. Thompson W. J., Appleman M. M., Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 1971 10 2 311 316 2-s2.0-0015231739
16. Ahn H. S., Crim W., Romano M., Sybertz E., Pitts B., Effects of selective inhibitors on cyclic nucleotide phosphodiesterase of rabbit aorta. Biochemical Pharmacology 1989 38 19 3331 3339 2-s2.0-0024454868 10.1016/0006-2952(89)90631-X (Pubitemid 19254124)
17. Podzuweit T., Nennstiel P., Muller A., Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3- nonyl) adenine. Cellular Signalling 1995 7 7 733 738 2-s2.0-0029088562 10.1016/0898-6568(95)00042-N
18. Harrison S. A., Reifsnyder D. H., Gallis B., Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Molecular Pharmacology 1986 29 5 506 514 2-s2.0-0022454622 (Pubitemid 16068905)
19. Reeves M. L., Leigh B. K., England P. J., The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochemical Journal 1987 241 2 535 541 2-s2.0-0023088944 (Pubitemid 17234191)
20. Gillespie P. G., Beavo J. A., Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M and B 22,948. Molecular Pharmacology 1989 36 5 773 781 2-s2.0-0024306482 (Pubitemid 20008225)
21. Schneider H. H., Schmiechen R., Brezinski M., Seidler J., Stereospecific binding of the antidepressant rolipram to brain protein structures. European Journal of Pharmacology 1986 127 1-2 105 115 2-s2.0-0022459284 (Pubitemid 16023615)
22. 3H]rolipram. Journal of Pharmacology and Experimental Therapeutics 2003 305 2 565 572 2-s2.0-0037405826 10.1124/jpet.102.047407 (Pubitemid 36459171)
23. Kanehiro A., Ikemura T., Mäkelä M. J., Lahn M., Joetham A., Dakhama A., Gelfand E. W., Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. American Journal of Respiratory and Critical Care Medicine 2001 163 1 173 184 2-s2.0-0035155146 (Pubitemid 32095268)
24. Hamelmann E., Schwarze J., Takeda K., Oshiba A., Larsen G. L., Irvin C. G., Gelfand E. W., Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. American Journal of Respiratory and Critical Care Medicine 1997 156 3 766 775 2-s2.0-0030800586 (Pubitemid 27396413)
25. Winterrowd G. E., Chin J. E., Flow cytometric detection of antigen-specific cytokine responses in lung T cells in a murine model of pulmonary inflammation. Journal of Immunological Methods 1999 226 1-2 105 118 2-s2.0-0032811720 10.1016/S0022-1759(99)00049-6 (Pubitemid 29336535)
26. Melgert B. N., Postma D. S., Geerlings M., Luinge M. A., Klok P. A., Van Der Strate B. W. A., Kerstjens H. A. M., Timens W., Hylkema M. N., Short-term smoke exposure attenuates ovalbumin-induced airway inflammation in allergic mice. American Journal of Respiratory Cell and Molecular Biology 2004 30 6 880 885 2-s2.0-2942517903 10.1165/rcmb.2003-0178OC (Pubitemid 38736913)
27. Busse W. W., Lemanske R. F., Asthma. New England Journal of Medicine 2001 344 5 350 362 2-s2.0-0035253291 10.1056/NEJM200102013440507 (Pubitemid 32107645)
28. Revets H., Pynaert G., Grooten J., De Baetselier P., Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses. Journal of Immunology 2005 174 2 1097 1103 2-s2.0-11844276029 (Pubitemid 40094307)
29. Vojdani A., Erde J., Regulatory T cells, a potent immunoregulatory target for CAM researchers: the ultimate antagonist (I). Evidence-based Complementary and Alternative Medicine 2006 3 1 25 30 2-s2.0-33745698831 10.1093/ecam/nek022 (Pubitemid 43999648)
30. Cher D. J., Mosmann T. R., Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by Th1 clones. Journal of Immunology 1987 138 11 3688 3694 2-s2.0-0023269443 (Pubitemid 17078235)
31. Bokkenheuser V. D., Shackleton C. H. L., Winter J., Hydrolysis of dietary flavonoid glycosides by strains of intestinal Bacteroides from humans. Biochemical Journal 1987 248 3 953 956 2-s2.0-0023548365 (Pubitemid 18012735)
32. Yang Y. L., Hsu H. T., Wang K. H., Hesperetin-7,3'- O -dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio. Journal of Biomedical Science 2011 18 1 84 10.1186/1423-0127-18-84
33. Namgoong S. Y., Son K. H., Chang H. W., Kang S. S., Kim H. P., Effects of naturally occurring flavonoids on mitogen-induced lymphocyte proliferation and mixed lymphocyte culture. Life Sciences 1994 54 5 313 320 2-s2.0-0028158941 10.1016/0024-3205(94)00787-X (Pubitemid 24049591)
34. Taube C., Duez C., Cui Z. H., Takeda K., Rha Y. H., Park J. W., Balhorn A., Donaldson D. D., Dakhama A., Gelfand E. W., The role of IL-13 in established allergic airway disease. Journal of Immunology 2002 169 11 6482 6489 2-s2.0-0036884608 (Pubitemid 36903499)
35. Vargaftig B. B., Singer M., Leukotrienes mediate murine bronchopulmonary hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine interleukin-13. American Journal of Respiratory Cell and Molecular Biology 2003 28 4 410 419 2-s2.0-0037385864 10.1165/rcmb.2002-0032OC (Pubitemid 36399362)
36. Tucker J., Fanta C. H., Golan D. E., Integrative inflammation pharmacology: asthma. Principles of Pharmacology the Pathophysiologic Basis of Drug Therapy 2005 Philadelphia, Pa, USA Lippincott Williams & Wilkins 695 705
37. Foster P. S., Hogan S. P., Ramsay A. J., Matthaei K. I., Young I. G., Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. Journal of Experimental Medicine 1996 183 1 195 201 2-s2.0-0030028768 10.1084/jem.183.1.195 (Pubitemid 26028759)
38. Clayton E., Bardi G., Bell S. E., Chantry D., Peter Downes C., Gray A., Humphries L. A., Rawlings D., Reynolds H., Vigorito E., Turner M., A crucial role for the p110 δ subunit of phosphatidylinositol 3-kinase in B cell development and activation. Journal of Experimental Medicine 2002 196 6 753 763 2-s2.0-0037119630 10.1084/jem.20020805
39. Okkenhaug K., Bilancio A., Farjot G., Priddle H., Sancho S., Peskett E., Pearce W., Meek S. E., Salpekar A., Waterfield M. D., Smith A. J. H., Vanhaesebroeck B., Impaired B and T cell antigen receptor signaling in p110 δ PI 3-kinase mutant mice. Science 2002 297 5583 1031 1034 2-s2.0-0037047590 10.1126/science.1073560 (Pubitemid 34856039)
40. Lee K. S., Lee H. K., Hayflick J. S., Lee Y. C., Puri K. D., Inhibition of phosphoinositide 3-kinase δ attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB Journal 2006 20 3 455 465 2-s2.0-33645827963 10.1096/fj.05-5045com (Pubitemid 44933322)
41. Emson C. L., Bell S. E., Jones A., Wisden W., McKenzie A. N. J., Interleukin (IL)-4-independent induction of immunoglobulin (Ig)E, and perturbation of T cell development in transgenic mice expressing IL-13. Journal of Experimental Medicine 1998 188 2 399 404 2-s2.0-0031852973 10.1084/jem.188.2.399 (Pubitemid 28357768)
42. Snapper C. M., Marcu K. B., Zelazowski P., The immunoglobulin class switch: beyond 'accessibility'. Immunity 1997 6 3 217 223 2-s2.0-0030933777 10.1016/S1074-7613(00)80324-6 (Pubitemid 27148588)
43. Stavnezer J., Molecular processes that regulate class switching. Current Topics in Microbiology and Immunology 1999 245 127 168 2-s2.0-0032858194
44. Haddad J. J., Land S. C., Tarnow-Mordi W. O., Zembala M., Kowalczyk D., Lauterbach R., Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor- α) biosynthesis in alveolar epithelial cells. Journal of Pharmacology and Experimental Therapeutics 2002 300 2 559 566
45. Haddad J. J., Land S. C., Tarnow-Mordi W. O., Zembala M., Kowalczyk D., Lauterbach R., Immunopharmacological potential of selective phosphodiesterase inhibition. II. Evidence for the involvement of an inhibitory- B/nuclear factor- B-sensitive pathway in alveolar epithelial cells. Journal of Pharmacology and Experimental Therapeutics 2002 300 2 567 576 2-s2.0-0036151665 10.1124/jpet.300.2.567 (Pubitemid 34106249)
46. Westfall D. P., Gerthoffer W. T., Webb R. C., Brody T. M., Larner J., Minneman K. P., Vasodilators and nitric oxide synthasein. Human Pharmacology Molecular to Clinical 1998 St. Louis, Mo, USA Mosby 239 247
47. Shih C. H., Lin L. H., Hsu H. T., Hesperetin, a selective phosphodiesterase 4 inhibitor, effectively suppresses ovalbumin-induced airway hyperresponsiveness without influencing xylazine/ketamine-induced anesthesia. Evidence-Based Complementary and Alternative Medicine 2012 2012 10 472897 10.1155/2012/472897
48. Robichaud A., Savoie C., Stamatiou P. B., Tattersall F. D., Chan C. C., PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 2001 40 2 262 269 2-s2.0-0035216330 10.1016/S0028-3908(00) 00142-8
49. Jin S. L., Richter W., Conti M., Beavo J. A., Francis S. H., Houslay M. D., Insights into the physiological functions of PDE4 from knockout mice. Cyclic Nucleotide Phosphodiesterases in Health and Disease 2007 Boca Raton, Fla, USA CRC Press 323 346